Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Sánchez‐Martínez, Eva María; Ruiz, Ramón García; Moneva-Leniz, Lya Magdalena; Mateu-Puchades, Almudena

doi:10.1111/dth.14054

Cited by 17 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DLQI and VAS of pain improved by ≥30% in 71.42% of patients in the absence of significant ustekinumab-related side effects [ 241 ]. In accordance with these findings, Sánchez-Martínez and colleagues, evaluating the effectiveness and safety of the ustekinumab dosing schedule approved for CD in 6 adalimumab-experienced HS patients (50% female), found that 50% of patients achieved HiSCR at week 12, without any drug-related side effects [ 242 ]. Rather recently, Scholl et al also reported the potential utility of a high-dose regimen of ustekinumab in their case series including 3 biologic-experienced HS patients (1 female and 2 males) [ 243 ].…”

Section: (New Medical) Therapeutical Approaches In Hsmentioning

confidence: 71%

Insights into the Pathogenesis of HS and Therapeutical Approaches

et al. 2021

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a debilitating, chronic, (auto)inflammatory disease primarily affecting apocrine gland-rich areas of the body. Although pathogenic mechanisms responsible for HS have not yet been fully elucidated, it is a multifactorial process whose main target is the terminal follicle. The role of the inflammatory process (and consequently of cytokine milieu) and of several other factors (genetics, lifestyle, hormonal status, microbiome, innate and adaptive immune systems) involved in HS pathogenesis has been investigated (and often defined) over the years with a view to transferring research results from bench to bedside and describing a unique and universally accepted pathogenetic model. This review will update readers on recent advances in our understanding of HS pathogenesis and novel (potential) medical therapies for patients with moderate-to-severe HS.

show abstract

Section: (New Medical) Therapeutical Approaches In Hsmentioning

confidence: 71%

Insights into the Pathogenesis of HS and Therapeutical Approaches

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 89 Furthermore, real-life observations support that it can be effectively and safely used in patients who develop paradoxical psoriasis while receiving anti-TNF-α treatment, 51 as well as for the treatment of hidradenitis suppurativa. 90 Safety profile and efficacy on extraintestinal manifestations also advocate in favor of ustekinumab as a reasonable candidate for the combination of targeted therapies, for patients with medical-refractory IBD without other medical options as well as for those with concomitant IBD and extraintestinal manifestations. 91 , 92 Moreover, unlike with anti-TNF-α drugs, treatment with ustekinumab is associated with a more durable efficacy over time, mainly due to its low rate of immunogenicity.…”

Section: Methodsmentioning

confidence: 99%

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab

Pugliese

Privitera

Fiorani

et al. 2022

Therap Adv Gastroenterol

View full text Add to dashboard Cite

As our comprehension of the pathogenic mechanisms of inflammatory bowel disease (IBD) increases, the therapeutic armamentarium for its treatment can expand, and novel target therapies join the treatment pipeline. Interleukin (IL)-12 and IL23 are two key cytokines responsible for promoting and perpetuating bowel inflammation in IBD. Ustekinumab is a monoclonal antibody directed against the shared p40 subunit of both cytokines, and it was recently approved for the treatment of ulcerative colitis (UC). In the pivotal phase III UNIFI trial, ustekinumab showed a superiority over placebo in both clinical and endoscopic outcomes; furthermore, it was characterized by a favorable safety profile, with a similar rate of adverse events as compared with placebo. Recent evidence from real-life experiences have started accumulating, generally confirming the effectiveness and safety figures emerged from the registration studies. However, most of these observational studies enrolled multirefractory patients; moreover, comparative data with other target therapies are lacking, leaving physicians without clear indications about the appropriate positioning of ustekinumab in the therapeutic pipeline for UC. This review examines the basis of targeting IL12-23 in UC therapy and summarizes the data from both clinical trials and real-life studies, to highlight the main evidence already available and the research gaps that need to be filled for the optimal usage of ustekinumab in UC.

show abstract

“…173 A retrospective study including six patients treated with this regime obtained the same clinical response. 174 Moreover, in a retrospective study, HiSCR was achieved by 9/10 patients treated with UST 90 mg every 8 weeks (without induction dose). 175 Whether higher doses are more effective in HS requires further evaluation in RCTs.…”

Section: Treatmentmentioning

confidence: 99%

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.

show abstract

Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

Cited by 17 publications

References 9 publications

Insights into the Pathogenesis of HS and Therapeutical Approaches

Insights into the Pathogenesis of HS and Therapeutical Approaches

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab

New perspectives on the treatment of hidradenitis suppurativa

Contact Info

Product

Resources

About